Supernus Pharmaceuticals (LTS:0LB2) Short Ratio


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
87 GF Score
Price $47.95
GF Value $38.94
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0LB2
87GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $47.95 is trading 23.1% above its estimated GF Value™ of $38.94. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Short Ratio:
  • GF Value™: $38.94 vs. price of $47.95 (23.1% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for LTS:0LB2

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.95
Price
$38.94
GF Value